AXA Framlington Biotech Fund - Z Acc
SpecialistPricing frequency
Daily
Dealing cut off time
11:00
Type
Unit Trust
Yield
–
NAV
660.70p
Income frequency
Semi-annually
Ongoing charge
0.82%
Latest actual NAV date
16-11-2026
ISIN
GB00B784NS11
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 31/10/2026 | % of assets |
|---|---|
| Vertex Pharmaceuticals Inc | 8.70 |
| Amgen Inc | 8.12 |
| Regeneron Pharmaceuticals Inc | 7.55 |
| Gilead Sciences Inc | 6.90 |
| argenx SE ADR | 4.71 |
| United Therapeutics Corp | 4.19 |
| Revolution Medicines Inc Ordinary Shares | 4.05 |
| Insmed Inc | 3.73 |
| BeOne Medicines Ltd ADR | 2.65 |
| Mirum Pharmaceuticals Inc | 2.43 |
Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.